This refresh
Data-driven refresh July 8, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,235 tickers); 1,772 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. DOCS — Doximity, Inc. · score 90.2
Health Information Services · price $21.69 · 1Y $24.37 · 5Y $35.68 · 10Y $52.93
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 22.1x B+ · PEG 0.59 A-
Why now. The Bull Rankings sees Doximity as a compelling growth compounder, leveraging its dominant digital platform for medical professionals. With a highly attractive PEG Ratio of 0.59, the market significantly undervalues its growth trajectory, which is backed by a robust profit margin of 30.4% and impressive free cash flow of $326m. The thesis rests on Doximity's continued ability to expand monetization of its core platform and specialized workflow tools like Ask and Scribe, driving persistent compounding.
Moat. Doximity's durable edge stems from a powerful network effect among medical professionals in the United States, reinforced by its HIPAA-compliant digital platform and integrated workflow tools like Ask and Scribe. This deep integration into clinical workflows creates high switching costs and trust, allowing the company to achieve a strong ROE of 20.6% through pricing power with pharmaceutical manufacturers and health systems. A competitor cannot quickly replicate this established network and the trust built around secure, compliant medical communication and tools.
Risk. The primary bear case centers on the potential for growth deceleration, as the reported revenue growth of 13.1% (FY YoY) might not justify its current P/E ratio of 22.1 if the pace slows further. Skeptics would argue that while profitable, the company's reliance on sponsored content from pharmaceutical manufacturers and health systems could face headwinds if industry marketing budgets tighten or competition for professional attention intensifies. A sustained decline in new member engagement or a significant dip in monetization rates for its personalized newsfeed would confirm the bear case.
Horizon. 1-3 yr $24.37 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $35.68 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $52.93 if current growth sustains into durable earnings power.
2. INTU — Intuit Inc. · score 89.5
Software - Application · price $272.10 · 1Y $486.61 · 5Y $712.45 · 10Y $1,057
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 16.6x A- · PEG 0.71 A-
Why now. Intuit's robust ecosystem of financial management tools, particularly in its Global Business Solutions segment with QuickBooks and Mailchimp, drives persistent growth. The company trades at a compelling PEG ratio of 0.71, indicating undervaluation relative to its 15.6% FY YoY revenue growth, while generating substantial $7.8B in TTM free cash flow. The crux lies in the enduring need for integrated financial and marketing solutions for small and mid-market businesses, ensuring sticky, recurring revenue streams.
Moat. Intuit's moat is built on high switching costs inherent in its core offerings like QuickBooks, which deeply embeds into small and mid-market business operations for financial management and payroll. The 22.2% ROE reflects pricing power derived from category leadership and the mission-critical nature of these services, making it difficult for competitors to dislodge established users. Furthermore, the integration of Mailchimp and Credit Karma creates a broader ecosystem, enhancing customer stickiness and data-driven insights.
Risk. Skeptics might point to the potential for increased competition in specific segments, particularly in consumer financial services or marketing automation, which could pressure Intuit's growth trajectory. Despite strong profitability, the company's P/E (TTM) of 16.6, while reasonable for its growth, could be vulnerable if the 15.6% revenue growth shows signs of deceleration. A sustained decline in new customer acquisition for QuickBooks or Mailchimp, leading to a noticeable drop in reported revenue growth rates, would confirm the bear case.
Horizon. 1-3 yr $486.61 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $712.45 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,057 if current growth sustains into durable earnings power.
3. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $89.88 · 1Y $103.36 · 5Y $151.33 · 10Y $224.49
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 14.1x A- · PEG 0.51 A-
Why now. Stride, Inc. represents a compelling growth opportunity, delivering a robust 17.9% FY YoY revenue expansion while trading at a remarkably low 14.1 P/E TTM. The company's ability to generate $414m in TTM free cash flow, coupled with a PEG ratio of just 0.51, indicates significant undervaluation for a business capitalizing on the persistent demand for its online curriculum and educational services for virtual and blended public schools. The market is failing to price in the sustained compounding power of its efficient growth.
Moat. Stride's durable edge stems from its comprehensive, technology-based ecosystem that integrates proprietary and third-party online curriculum with software systems and educational services. This "integrated package of systems, services, products, and professional expertise" creates significant switching costs for public schools and school districts, making it difficult for clients to transition away once embedded. The company's 18.8% Return on Equity reflects its operational efficiency in delivering these specialized, individualized learning solutions.
Risk. Skeptics would argue that Stride's significant drop from its 52-week high of $171.17 to the current $89.88 reflects underlying concerns about the sustainability of its growth in a competitive education landscape. Despite robust revenue growth, the low analyst coverage (2 analysts) suggests limited institutional conviction, potentially due to perceived risks from new entrants or evolving government funding for virtual and blended public schools. A sustained deceleration in its 17.9% revenue growth, or a material contraction in its 12.2% profit margin, would confirm that competitive pressures are indeed eroding its market position.
Horizon. 1-3 yr $103.36 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $151.33 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $224.49 if current growth sustains into durable earnings power.
4. ADBE — Adobe Inc. · score 89.2
Software - Application · price $220.94 · 1Y $272.48 · 5Y $398.93 · 10Y $591.79
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 12.6x A · PEG 0.60 A-
Why now. Adobe's Digital Media subscription engine is now compounding revenue at a 10.5% YoY pace, driven by Creative Cloud and Photoshop, while its free cash flow of $10.3B on a $87.8B market cap delivers a 12% yield and its ultra‑high ROE of 62.8% shows pricing power; combined with a low P/E of 12.6x the stock is a cheap growth engine, and the thesis rests on the relentless stickiness of subscription revenue.
Moat. The Creative Cloud suite locks in photographers, video editors, designers and marketers through annual licenses, creating a high‑switching‑cost ecosystem that competitors cannot replicate quickly. Adobe’s integrated Digital Experience platform adds cross‑sell power, letting brands manage content, analytics and commerce in one place, which fuels the 28.7% profit margin and sustains the 62.8% ROE.
Risk. A bear sees Adobe’s growth decelerating as the Digital Media market saturates; the 10.5% revenue growth is modest for a high‑growth name, and a beta of 1.43 makes the stock vulnerable to market swings. The debt‑to‑equity ratio of 0.61 could limit flexibility if capital‑intensive AI investments stall, and a breach of the 52‑week low ($190.12) would signal a loss of confidence. A sustained drop below $190 would confirm the downside case.
Horizon. 1-3 yr $272.48 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $398.93 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $591.79 if current growth sustains into durable earnings power.
5. PCTY — Paylocity Holding Corporation · score 88.3
Software - Application · price $115.21 · 1Y $152.58 · 5Y $223.39 · 10Y $331.39
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 24.6x B+ · PEG 0.89 B+
Why now. Paylocity’s cloud‑based payroll and HR suite is locking in mid‑market employers with its on‑demand payment and talent solutions, creating a recurring revenue engine that compounds. The business is delivering 14.8% YoY revenue growth, 16.1% profit margin and a stellar 21.9% ROE, while trading at a sub‑2× PEG of 0.89. The thesis rests on the ability to keep expanding the payroll‑to‑talent flywheel, which drives sustainable cash‑flow growth.
Moat. The integrated payroll, tax, HR compliance dashboard and talent modules embed critical employee data across finance and HR, creating high switching costs for customers. This lock‑in fuels pricing power that lifts ROE above 20%, and the low 0.11 debt‑to‑equity ratio lets Paylocity reinvest cash without leverage constraints, a combination rivals can’t duplicate quickly.
Risk. The stock trades at a forward P/E of 24.6 despite a modest 14.8% growth rate, implying the market may be over‑paying if revenue growth stalls below 10% YoY or margins dip under 14%. A slowdown or a competitive win by larger HCM players would pressure the valuation and could push the price back toward the 52‑week low of $92.99, confirming the bear case.
Horizon. 1-3 yr $152.58 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $223.39 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $331.39 if current growth sustains into durable earnings power.
6. NBIX — Neurocrine Biosciences, Inc. · score 87.1
Drug Manufacturers - Specialty & Generic · price $178.24 · 1Y $197.95 · 5Y $289.82 · 10Y $429.93
FCF $831m C+ · Rev +21.4% A- · D/E 0.14 B+ · P/E 27.5x B · PEG 0.49 A
Why now. Neurocrine Biosciences is a high-quality compounder, driven by robust demand for its specialized neurological and psychiatric treatments, particularly INGREZZA for tardive dyskinesia. The company's impressive 21.4% revenue growth (FY YoY) combined with a highly attractive 0.49 PEG ratio signals strong underlying business momentum that is undervalued by the market. With a healthy 21.6% profit margin and significant free cash flow of $831m, NBIX is well-positioned to fund its promising clinical pipeline, ensuring sustained long-term expansion.
Moat. Neurocrine's durable edge stems from its deep specialization and intellectual property in complex neurological, psychiatric, endocrine, and immunological disorders, exemplified by key products like INGREZZA. The high barriers to entry in developing and commercializing pharmaceuticals for these conditions, including extensive R&D and rigorous regulatory processes, protect its market position. This specialization enables strong pricing power and contributes to its robust 19.6% Return on Equity, making it difficult for competitors to quickly replicate its success.
Risk. The primary risk for Neurocrine Biosciences lies in its reliance on successful clinical development and market penetration of its pipeline candidates, such as NBI-1076986 for movement disorders or Osavampator for major depressive disorder. The current P/E of 27.5 suggests the market has high expectations for these future growth drivers. Should any late-stage clinical trials fail or key products face unexpected competition, the company's future growth trajectory could be significantly impacted, confirming the bear case and making its current valuation unsustainable.
Horizon. 1-3 yr $197.95 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $289.82 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $429.93 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 86.9
Biotechnology · price $9.16 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
FCF $108m C · Rev +19.6% B+ · D/E 1.11 C · P/E 13.5x A- · PEG 0.69 A-
Why now. ADMA Biologics presents a compelling growth story, leveraging its specialized plasma-derived biologics like BIVIGAM and ASCENIV for primary humoral immunodeficiency (PI). The company boasts robust revenue growth of +19.6% (FY YoY) and an impressive profit margin of 32.4%, translating into strong free cash flow of $108m (TTM). This potent combination of high growth and profitability, reflected in a low PEG ratio of 0.69, indicates ADMA is effectively expanding its market share in critical care segments, with continued demand for its life-sustaining treatments being the crux.
Moat. ADMA's durable edge stems from its vertically integrated operations, encompassing ADMA BioManufacturing and Plasma Collection Centers, which secure the critical supply chain for its specialty plasma-derived biologics such as BIVIGAM and ASCENIV. This control over raw material and production, combined with the high regulatory hurdles and complex manufacturing processes inherent to plasma-derived products, creates significant barriers to entry. The company's exceptional ROE of 42.4% is a direct result of the pricing power derived from its essential, specialized treatments for immune deficiencies and infectious diseases.
Risk. The primary concern for ADMA is its elevated debt-to-equity ratio of 1.11, which could constrain future flexibility or amplify risks if market conditions for its specialty biologics shift. While growth is strong, the biopharmaceutical sector is susceptible to new competitive entrants or alternative therapies for conditions like PI or Hepatitis B, potentially eroding the market for its BIVIGAM, ASCENIV, and Nabi-HB products. A sustained deceleration in revenue growth below the current 19.6% would confirm the bear case, signaling increased competition or market saturation.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. NVDA — NVIDIA Corporation · score 86.1
Semiconductors · price $204.12 · 1Y $301.62 · 5Y $441.60 · 10Y $655.09
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 31.2x B · PEG 0.60 A-
Why now. NVIDIA's Compute & Networking segment is the engine of AI‑driven data‑center growth, delivering a revenue surge of 65.5% YoY while generating free cash flow of $119.1 B on a 31.2× PE, proving investors are paying a premium for its AI moat. A rock‑solid balance sheet with a debt‑to‑equity of 0.07 and an 81.7% ROE lets the company reinvest cash at high returns, ensuring compounding persists. The whole thesis hinges on relentless AI demand in the data‑center segment.
Moat. The Compute & Networking segment locks customers into NVIDIA's proprietary GPU and AI software stack, creating massive switching costs for hyperscale cloud providers and enterprise data centers. Its 81.7% ROE stems from pricing power derived from category leadership in AI‑accelerated computing, a position rivals cannot replicate quickly due to the deep IP ecosystem and developer network. This high‑margin, high‑growth engine protects earnings even as competition intensifies.
Risk. A 31.2× PE and a beta of 2.21 signal that the stock is highly valued and volatile; any slowdown in AI spending or a shift to alternative accelerators would compress multiples sharply. The business is heavily weighted to the data‑center segment, so a deceleration of revenue growth below 30% YoY would expose the valuation premium. The bear case is confirmed if the 12‑month forward PE falls below 20× or if quarterly revenue growth stalls under 30%.
Horizon. 1-3 yr $301.62 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $441.60 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $655.09 if current growth sustains into durable earnings power.
9. EXLS — ExlService Holdings, Inc. · score 85.7
Information Technology Services · price $27.38 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 17.4x A- · PEG 0.87 B+
Why now. EXLS is a compelling growth opportunity, trading at a significant discount despite its strong position as a "data and artificial intelligence (“AI”) company." Its highly attractive 0.87 PEG ratio, combined with robust 13.6% FY YoY revenue growth, suggests the market is underpricing its consistent execution in providing specialized "digital operations and solutions and analytics-driven services" to critical sectors. With the stock trading near its 52-week low, the analyst consensus 1-year target of $41.75 represents substantial upside, indicating a clear path for re-rating as its AI and analytics capabilities continue to drive client value.
Moat. EXLS's durable edge stems from its deep integration and specialized expertise in "analytics-driven services" for complex industries like "Insurance" and "Healthcare and Life Sciences." Providing mission-critical functions such as "claims management, premium and benefit administration, and actuarial and risk analytics" creates high switching costs for clients. This specialized, embedded service model, coupled with its "AI" capabilities, underpins its exceptional 32.3% Return on Equity, reflecting strong pricing power and recurring revenue streams that are difficult for competitors to replicate quickly.
Risk. The primary bear case for EXLS centers on intense competition within the "Information Technology Services" sector, particularly in the rapidly evolving "AI" and "analytics-driven services" space. While growth has been solid, the company's current price of $27.38, near its 52-week low, suggests investor concern about sustained competitive pressure potentially impacting future growth rates or profitability. A sustained deceleration in its 13.6% revenue growth or a material contraction in its 11.7% profit margin would confirm that competitors are successfully eroding its market position or pricing power.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
10. CPRX — Catalyst Pharmaceuticals, Inc. · score 84.6
Biotechnology · price $31.47 · 1Y $31.67 · 5Y $46.36 · 10Y $68.78
FCF $208m C · Rev +19.8% B+ · D/E 0.00 A · P/E 18.2x A- · PEG 0.92 B+
Why now. Catalyst Pharmaceuticals is a high-quality compounder, delivering robust growth in the specialized rare disease market with products like Firdapse for LEMS and AGAMREE for Duchenne Muscular Dystrophy. The company boasts impressive profitability, evidenced by its 37.1% profit margin and 19.8% FY YoY revenue growth, yet trades at a compelling 0.92 PEG ratio. This combination of strong operational performance and attractive valuation suggests continued outperformance as its rare disease portfolio expands and matures.
Moat. Catalyst Pharmaceuticals' durable edge stems from its strategic focus on developing and commercializing medicines for rare diseases, such as Firdapse for LEMS and AGAMREE for Duchenne Muscular Dystrophy. This niche specialization creates significant barriers to entry for competitors, allowing the company to maintain pricing power and generate a robust 21.9% Return on Equity. The high switching costs for patients with chronic rare conditions further solidify its market position, ensuring sustained revenue streams from its established product portfolio.
Risk. Bears argue that Catalyst Pharmaceuticals' current valuation, with the stock trading near its $32.56 52-week high and just below the $31.67 analyst consensus 1-year target, already prices in its strong growth. While impressive, the company's reliance on a concentrated portfolio of rare disease treatments like Firdapse and Fycompa presents inherent market concentration risk. A concrete signal confirming the bear case would be a material slowdown in revenue growth from the current 19.8% or the emergence of a highly effective, competitive treatment for one of its core indications.
Horizon. 1-3 yr $31.67 (analyst consensus (n=3)) — fundamentals + valuation re-rating. 5 yr $46.36 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $68.78 if current growth sustains into durable earnings power.
11. IT — Gartner, Inc. · score 84.5
Information Technology Services · price $134.68 · 1Y $165.00 · 5Y $241.58 · 10Y $358.36
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 13.3x A · PEG 0.55 A-
Why now. Gartner's core Insights segment, delivering subscription services and expert access, provides a stable, compounding revenue stream that generates significant free cash flow, currently undervalued by the market. A peg_ratio of 0.55 suggests the market is not fully appreciating its growth relative to its valuation, especially given $1.3b in free cash flow against a $9.0b market cap. The consistent cash generation from its mission-critical insights underpins a compelling valuation for a company with durable client relationships.
Moat. The Insights segment, delivering access to published content, data, benchmarks, and a network of business and technology experts, creates high switching costs. Organizations embed Gartner's specific insights into their strategic decision-making and performance monitoring, making it difficult and disruptive to transition to alternative providers. The Conferences segment further strengthens this by fostering a community for executives and teams to learn, share, and network, deepening client stickiness and reinforcing its position as a trusted advisor.
Risk. The primary bear case centers on Gartner's modest revenue_growth_pct of 3.7% (FY YoY), which, despite a low peg_ratio of 0.55, may not justify its "growth" classification if it fails to accelerate. The significant drop from its week_52_high of $401.6 to the current price of $134.68 suggests investors have already re-rated the stock for slower growth. A sustained decline in new client acquisition or an increase in churn rates within the high-margin Insights segment would confirm a structural slowdown.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $241.58 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $358.36 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 83.9
Information Technology Services · price $85.99 · 1Y $142.82 · 5Y $209.11 · 10Y $310.20
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 12.4x A · PEG 0.45 A
Why now. EPAM is a deeply undervalued growth engine, trading at an absurdly low PEG Ratio of 0.45 and a P/E of 12.4 despite delivering 15.4% FY YoY revenue growth in mission-critical digital platform engineering and AI services. The market is failing to price in its robust $544m in TTM Free Cash Flow, which provides ample capital for continued innovation and shareholder returns. The crux is that EPAM's essential role in enterprise digital transformation and AI adoption will drive consistent compounding, eventually forcing a significant re-rating.
Moat. EPAM's durable edge stems from its deep integration into client operations through complex digital platform engineering and software development, creating high switching costs once solutions like cross-platform migration and AI implementations are customized. Its specialized expertise in areas such as cloud services, data/analytics/artificial intelligence, and cybersecurity ensures clients rely on EPAM for mission-critical, bespoke solutions, reinforcing long-term relationships. This sticky client base, built on highly specialized engineering services, underpins its consistent 11.3% ROE.
Risk. The market's brutal repricing, evidenced by the stock's fall from a 52-week high of $222.53 to its current $85.99, reflects fears that EPAM's growth in digital platform engineering and software development is highly susceptible to cyclical downturns in enterprise IT spending. Its 7% profit margin could face further compression from intense competition in cloud and AI services, or from wage inflation for its highly skilled engineers. A sustained deceleration in revenue growth below 10%, coupled with further margin erosion, would confirm that EPAM's premium services are becoming commoditized.
Horizon. 1-3 yr $142.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $209.11 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $310.20 if current growth sustains into durable earnings power.
13. DXCM — DexCom, Inc. · score 83
Medical Devices · price $74.06 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
FCF $1.4b C+ · Rev +15.6% B+ · D/E 0.47 B · P/E 31.8x C+ · PEG 1.35 B
Why now. DexCom is a compelling growth story, poised to compound capital at a high rate by expanding its continuous glucose monitoring (CGM) systems beyond traditional insulin users into the massive prediabetes and non-insulin dependent Type 2 diabetes markets with products like Stelo. This strategic expansion underpins its robust 15.6% revenue growth and exceptional 31.5% Return on Equity, demonstrating efficient capital deployment and market capture. The crux of the thesis rests on DXCM's ability to successfully penetrate these broader patient populations, sustaining its impressive 19.3% profit margin as it scales.
Moat. DXCM's durable edge stems from its technological leadership and established ecosystem within the CGM market, particularly with its integrated Dexcom G7 and G6 systems, which create significant switching costs for patients and clinicians. The company's impressive 31.5% Return on Equity is a direct result of its pricing power and category leadership, reinforced by intellectual property and regulatory hurdles that protect its core offerings. Furthermore, the Dexcom Share remote monitoring system and Follow application deepen engagement, making its solutions sticky and difficult for competitors to replicate quickly.
Risk. The primary bear case against DXCM centers on its elevated valuation and the increasing competitive landscape in the broader metabolic health market. With a P/E of 31.8 and a PS of 5.9 against a 15.6% revenue growth rate, the market is pricing in significant future growth, leaving little room for error. Furthermore, its beta of 1.45 indicates high sensitivity to market downturns, and any deceleration in the adoption of new products like Stelo or increased pricing pressure from emerging competitors could compress margins. A sustained decline in revenue growth rates below current levels would confirm the bear case and challenge the bull thesis.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
14. CARG — CarGurus, Inc. · score 82.8
Auto & Truck Dealerships · price $34.19 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 18.0x B+ · PEG 1.08 B+
Why now. CarGurus is a high-quality compounder leveraging its online automotive platform to connect car shoppers with an extensive network of dealers, driving robust financial performance. Its 13.7% FY YoY revenue growth is efficiently converted into $293m in TTM free cash flow, while trading at a reasonable 18 times TTM earnings. The thesis rests on the continued expansion and monetization of its integrated suite of products, particularly the Digital Deal option, which streamlines the vehicle purchase process online and solidifies its market position.
Moat. CarGurus' durable edge stems from the powerful network effect of its online automotive marketplace, which connects a large audience of car shoppers with an extensive network of dealers, creating significant value for both sides. This self-reinforcing ecosystem, coupled with its integrated suite of products like Digital Deal and Dealership Mode, fosters high switching costs for dealers and consumers. The company's exceptional 62.9% Return on Equity demonstrates its ability to generate outsized profits, driven by pricing power derived from its category leadership and the operational leverage inherent in its platform model.
Risk. The primary bear case for CarGurus centers on the cyclical nature of the auto industry and intense competition within the online automotive marketplace, which could pressure its core revenue streams from dealer subscription fees and advertising. Its 0.79 debt-to-equity ratio, while manageable, adds a layer of financial risk should a significant downturn in vehicle sales impact its cash flow generation. A sustained deceleration in its 13.7% revenue growth, coupled with increasing competitive pressure on its dealer network, would confirm that its growth premium is unwarranted.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
15. VEEV — Veeva Systems Inc. · score 82.2
Health Information Services · price $188.17 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 33.4x C+ · PEG 0.87 B+
Why now. Veeva’s dominance in the life‑sciences cloud, anchored by its Vault CRM Suite and Data Cloud, fuels a relentless revenue engine that is expanding at 16.3% YoY while delivering $1.7B of free cash flow and a compelling 0.87 PEG ratio, proving the business is both growing and efficiently priced. The low‑debt balance sheet (D/E 0.01) and sub‑1× beta give investors upside with limited downside, making the current price a launchpad for a multi‑year compounding run. The thesis rests on the fact that Veeva’s integrated cloud stack locks in pharma and biotech customers, ensuring the growth engine stays hot.
Moat. Veeva’s Vault platform creates a high‑switching‑cost ecosystem: pharmaceutical and biotech firms embed Veeva’s CRM, content, and analytics tools across R&D, compliance, and commercial operations, making migration costly and time‑consuming. This lock‑in is reinforced by the company’s 28.4% profit margin, which reflects pricing power derived from its category‑leadership in regulated cloud solutions that rivals cannot replicate quickly.
Risk. The stock trades at a lofty 33.4 P/E, implying the market expects growth to accelerate even as revenue growth has slowed to a modest 16.3% YoY, raising the risk of a valuation correction if the pace falters. A beta of 0.94 signals sensitivity to broader market swings, and any loss of a major pharma client to a competing cloud provider would compress margins and erode the cash‑flow cushion. A sustained dip in revenue growth below 12% would trigger the bear case and invalidate the upside thesis.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
16. RMD — ResMed Inc. · score 81.7
Medical Instruments & Supplies · price $205.84 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
FCF $1.8b C+ · Rev +9.8% B · D/E 0.13 B+ · P/E 19.8x B+ · PEG 1.28 B
Why now. ResMed’s cloud‑connected NightOwl and ApneaLink Air platforms lock clinicians into a recurring software ecosystem that fuels high‑margin growth, and that engine is already delivering 9.8% YoY revenue growth, a rock‑solid 27.4% profit margin, and $1.8 B of free cash flow. The business trades at a modest PEG of 1.28 and a P/E of 19.8, meaning the market is undervaluing a compounder that can keep expanding its SaaS‑driven recurring revenue. The thesis rests on the relentless compounding of software‑enabled services around sleep apnea diagnostics.
Moat. ResMed’s integrated hardware‑software stack—ApneaLink Air for clinic‑based diagnostics and NightOwl for at‑home, cloud‑connected monitoring—creates high switching costs for sleep centers that have built care pathways around its data platform. This lock‑in, combined with a 23.4% ROE driven by pricing power in the premium sleep‑health segment, gives the company a durable edge that rivals cannot replicate quickly.
Risk. The growth story could stall: a 9.8% revenue increase is modest for a high‑growth name, and the current P/E of 19.8 implies the market is already pricing in future acceleration; any slowdown would compress margins and push the PEG above 1.5. A bear would see the stock slip back toward its 52‑week low of $180.27 if quarterly earnings miss the margin trajectory, confirming the over‑optimistic valuation.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
17. CVSA — Covista Inc. · score 81.4
Education & Training Services · price $130.85 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 19.0x B · PEG 0.88 B+
Why now. Covista Inc. is a compelling growth story, uniquely positioned in the high-demand healthcare education sector, evidenced by its robust 12.9% FY YoY revenue growth. Its strong operational efficiency delivers a healthy 12.3% profit margin, while a 0.88 PEG ratio suggests the market is underpricing this growth relative to earnings. The crux of the thesis rests on the persistent, inelastic demand for skilled professionals in nursing, medical, and veterinary fields, which Covista's Chamberlain and American University of the Caribbean programs are purpose-built to address.
Moat. Covista's durable edge stems from its established accreditation and specialized curriculum across its Chamberlain, Walden, and Medical and Veterinary segments, particularly in high-barrier-to-entry fields like nursing and medical postsecondary education. The company's extensive program offerings, from bachelor's to doctoral degrees and online certificates, create significant switching costs for students seeking comprehensive and recognized qualifications. This breadth and depth, combined with a 17.2% ROE, make it difficult for new entrants to quickly replicate Covista's integrated educational ecosystem and reputation.
Risk. The primary bear case against Covista centers on potential regulatory shifts within the education sector, particularly concerning federal funding or accreditation standards, which could disproportionately impact its multi-segment operations across the US and Caribbean. While its debt-to-equity of 0.54 is manageable, any significant slowdown in enrollment growth or increased competition in online learning could pressure its $336m TTM FCF generation. The concrete signal confirming the bear case would be a sustained decline in new student enrollments across its core healthcare programs, leading to a contraction in profit margins.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
18. META — Meta Platforms, Inc. · score 81.4
Internet Content & Information · price $603.12 · 1Y $828.17 · 5Y $1,213 · 10Y $1,799
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 21.9x B · PEG 0.87 B+
Why now. Meta Platforms remains a high-quality compounder, with its dominant Family of Apps (FoA) segment driving robust financial performance and funding future innovation. The company's impressive 22.2% (FY YoY) revenue growth, coupled with a 32.8% profit margin, demonstrates the enduring monetization power of its platforms like Facebook and Instagram. A PEG ratio of just 0.87 suggests the market is still underappreciating this compounding growth, making the sustained engagement across its vast user base the crux of its persistent outperformance.
Moat. Meta's formidable moat stems from the powerful network effects embedded within its Family of Apps (FoA) segment, particularly Facebook, Instagram, and Messenger. These platforms enable billions to connect and share, creating high switching costs and making it exceptionally difficult for new entrants to replicate their scale and user engagement. This category leadership and the resulting data advantage are key drivers behind its exceptional 29% Return on Equity, allowing for sustained pricing power in advertising and continued investment in its ecosystem.
Risk. The primary bear case centers on the substantial capital allocation to the Reality Labs (RL) segment, which, while promising, carries significant execution risk and could be a long-term drag on profitability if monetization remains elusive. Despite its robust core, Meta's high 1.25 beta indicates elevated sensitivity to market downturns, and the current price of $603.12, significantly below its 52-week high of $796.25, suggests investor skepticism about future growth drivers. A sustained deceleration in Family of Apps revenue growth, coupled with continued, substantial losses from Reality Labs, would confirm the bear thesis and pressure the stock further.
Horizon. 1-3 yr $828.17 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $1,213 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,799 if current growth sustains into durable earnings power.
19. QCOM — QUALCOMM Incorporated · score 79.8
Semiconductors · price $186.56 · 1Y $216.55 · 5Y $317.05 · 10Y $470.32
FCF $12.5b A- · Rev +13.7% B+ · D/E 0.56 C+ · P/E 20.1x B+ · PEG 0.59 A-
Why now. The bull case hinges on QCT’s 5G chipset dominance fueling mobile and automotive connectivity, delivering a compounding revenue engine; the business is already growing 13.7% YoY, converting that into a hefty 22.3% profit margin and a ROE of 36.4%, while generating $12.5B of free cash flow – the compounding engine rests on relentless 5G rollout and expanding automotive IoT demand.
Moat. Qualcomm’s moat lives in its massive patent portfolio that powers the QTL licensing stream and forces handset makers to lock‑in its QCT chips; the high ROE stems from pricing power as the only supplier of integrated 5G solutions for most flagship devices, and the switching cost of re‑architecting silicon and software makes rivals’ entry extremely costly.
Risk. The bear case points to intensifying competition in 5G silicon and automotive connectivity that could erode margins, while a PE of 20.1 suggests the market has already priced in growth; a beta of 1.64 amplifies downside on any market pull‑back, and a slowdown in revenue growth below the current 13.7% would trigger a sell‑off – a sustained margin dip below 20% would confirm the downside.
Horizon. 1-3 yr $216.55 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $317.05 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $470.32 if current growth sustains into durable earnings power.
20. PODD — Insulet Corporation · score 79.6
Medical Devices · price $157.46 · 1Y $239.42 · 5Y $350.53 · 10Y $519.99
FCF $416m C · Rev +30.7% A · D/E 0.78 C+ · P/E 36.8x C+ · PEG 1.41 B
Why now. Insulet Corporation is a high-quality compounder poised for continued expansion, driven by the strong adoption of its Omnipod 5 automated insulin delivery system in the critical diabetes management market. The company's impressive 30.7% revenue growth, coupled with robust $416m in free cash flow, demonstrates both market capture and financial strength. With the stock trading near its 52-week low of $138.79 and a consensus 1-year analyst target of $239.42, the market is underpricing the persistent demand for innovative, user-friendly insulin delivery solutions.
Moat. Insulet's durable edge stems from its proprietary Omnipod platform, particularly the Omnipod 5's embedded AID algorithm and seamless integration with third-party continuous glucose monitors. This technology creates significant switching costs for users who rely on its convenience and efficacy for daily diabetes management, making it difficult for competitors to dislodge. The company's exceptional 23.2% Return on Equity reflects its category leadership and pricing power within the automated insulin delivery system market, a testament to its innovation and patient loyalty.
Risk. The primary bear case for Insulet centers on its elevated valuation and potential competitive pressures in the rapidly evolving medical device sector. A P/E TTM of 36.8 suggests significant future growth is already priced in, leaving little room for execution missteps or increased competition from alternative insulin delivery systems. The relatively high debt-to-equity ratio of 0.78, while manageable, could become a concern if revenue growth for the Omnipod 5 decelerates faster than anticipated, signaling market saturation or a superior competitive offering.
Horizon. 1-3 yr $239.42 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $350.53 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $519.99 if current growth sustains into durable earnings power.
21. MELI — MercadoLibre, Inc. · score 79.4
Internet Retail · price $1809.38 · 1Y $2,209 · 5Y $3,234 · 10Y $4,797
FCF $11.8b A- · Rev +34.3% A · D/E 1.70 C+ · P/E 47.7x C · PEG 1.11 B+
Why now. MercadoLibre is a compounding machine, leveraging its integrated ecosystem where the Mercado Libre Marketplace fuels its high-growth Mercado Pago financial technology platform. With revenue growth at 34.3% and a robust free cash flow of $11.8b, the company continues to expand its market dominance, making its 1.11 PEG ratio highly attractive. The thesis rests on the continued synergy and expansion of its commerce and fintech offerings across its key Latin American markets.
Moat. MELI's durable edge stems from the powerful network effects created by its interconnected ecosystem, where Mercado Libre Marketplace users are seamlessly integrated into Mercado Pago's financial services. This comprehensive suite, including Mercado Fondo, Mercado Credito, and Mercado Envios, creates significant switching costs and data advantages that are difficult for competitors to replicate. The company's impressive 26.4% ROE is a direct result of this integrated platform's ability to cross-sell and retain users efficiently, driving superior capital allocation and profitability.
Risk. Skeptics point to MELI's elevated valuation and significant leverage as potential headwinds, with a TTM P/E of 47.7 and a Debt-to-Equity ratio of 1.7. The company's high beta of 1.34 also indicates sensitivity to market volatility, which could exacerbate drawdowns. A sustained deceleration in revenue growth below its historical trend, or a material increase in non-performing loans within its Mercado Credito segment, would confirm the bear case and challenge the long-term bull thesis.
Horizon. 1-3 yr $2,209 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,234 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,797 if current growth sustains into durable earnings power.
22. DECK — Deckers Outdoor Corporation · score 78.6
Footwear & Accessories · price $102.22 · 1Y $126.86 · 5Y $160.15 · 10Y $205.39
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.6x A- · PEG 1.32 B
Why now. Footwear & Accessories · market cap $14.2b. 19% off the 52-week high of $126.50. 21 sell-side analysts rate this a Buy with a mean 1-yr target of $126.86 (implying +24% upside).
Moat. Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 41% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 107% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — multiple re-rating thesis requires a catalyst. 5 yr $160.15 at ~9% CAGR — dividend + buyback compounding. 10 yr $205.39 if the moat survives secular pressure.
23. NFLX — Netflix, Inc. · score 77.9
Entertainment · price $75.59 · 1Y $113.71 · 5Y $166.49 · 10Y $246.97
FCF $11.9b A- · Rev +15.9% B+ · D/E 0.54 B · P/E 24.4x B · PEG 1.49 B
Why now. Entertainment · market cap $318.3b. Down 41% from 52-week high of $128.96 — deep drawdown territory. Revenue growing +16%, comfortably above the S&P median. 44 sell-side analysts rate this a Buy with a mean 1-yr target of $113.71 (implying +50% upside).
Moat. Net margin 29% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $318.3b market cap places it among the largest companies in the sector — distribution, R&D, and customer-acquisition costs amortize across a base peers can't replicate.
Risk. Down 41% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.52 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $113.71 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $166.49 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $246.97 if current growth sustains into durable earnings power.
24. FISV — Fiserv, Inc. · score 76
Sector n/a · price $50.60 · 1Y $69.77 · 5Y $88.08 · 10Y $112.96
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.6x A- · PEG 2.38 C
Why now. Sector n/a · market cap $27.0b. Down 71% from 52-week high of $171.77 — deep drawdown territory. 26 sell-side analysts rate this a Hold with a mean 1-yr target of $69.77 (implying +38% upside).
Moat. Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 129% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 71% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $69.77 (analyst consensus (n=26)) — multiple re-rating thesis requires a catalyst. 5 yr $88.08 at ~12% CAGR — dividend + buyback compounding. 10 yr $112.96 if the moat survives secular pressure.
25. ULTA — Ulta Beauty, Inc. · score 74.9
Specialty Retail · price $455.11 · 1Y $623.58 · 5Y $912.99 · 10Y $1,354
FCF $1.1b C+ · Rev +9.7% B · D/E 0.89 B · P/E 17.1x B+ · PEG 1.57 C+
Why now. Specialty Retail · market cap $19.6b. Down 36% from 52-week high of $714.97 — deep drawdown territory. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $623.58 (implying +37% upside).
Moat. ROE 46% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 95% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Down 36% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon. 1-3 yr $623.58 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $912.99 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,354 if current growth sustains into durable earnings power.
26. YUMC — Yum China Holdings, Inc. · score 74.7
Restaurants · price $42.72 · 1Y $61.34 · 5Y $89.81 · 10Y $133.23
FCF $931m C+ · Rev +4.4% C+ · D/E 0.38 A- · P/E 16.4x B+ · PEG 1.06 B+
Why now. Restaurants · market cap $14.8b. Down 27% from 52-week high of $58.39 — deep drawdown territory. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $61.34 (implying +44% upside).
Moat. ROE 17% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 98% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $61.34 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $89.81 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $133.23 if current growth sustains into durable earnings power.
27. EME — EMCOR Group, Inc. · score 73.8
Engineering & Construction · price $768.98 · 1Y $1,000 · 5Y $1,263 · 10Y $1,619
FCF $1.1b C+ · Rev +16.6% B+ · D/E 0.13 A- · P/E 25.9x B+ · PEG 0.42 A
Why now. Engineering & Construction · market cap $34.2b. 19% off the 52-week high of $951.96. Revenue growing +17%, comfortably above the S&P median. PEG 0.42 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,000 (implying +30% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,000 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,263 at ~10% CAGR — dividend + buyback compounding. 10 yr $1,619 if the moat survives secular pressure.
28. VST — Vistra Corp. · score 73.7
Utilities - Independent Power Producers · price $154.82 · 1Y $222.89 · 5Y $281.39 · 10Y $360.88
FCF $1.8b C+ · Rev +19.1% B+ · D/E 3.55 D · P/E 25.9x C · PEG 0.47 A
Why now. Utilities - Independent Power Producers · market cap $52.2b. Down 30% from 52-week high of $219.82 — deep drawdown territory. Revenue growing +19%, comfortably above the S&P median. PEG 0.47 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $222.89 (implying +44% upside).
Moat. Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 40% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. $52.2b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. D/E 3.55 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon. 1-3 yr $222.89 (analyst consensus (n=18)) — multiple re-rating thesis requires a catalyst. 5 yr $281.39 at ~13% CAGR — dividend + buyback compounding. 10 yr $360.88 if the moat survives secular pressure.
29. ALLE — Allegion plc · score 73.2
Security & Protection Services · price $134.99 · 1Y $165.18 · 5Y $241.84 · 10Y $358.76
FCF $683m C+ · Rev +7.8% B · D/E 1.06 C+ · P/E 18.5x A- · PEG 2.15 C
Why now. Security & Protection Services · market cap $11.6b. Down 26% from 52-week high of $183.11 — deep drawdown territory. 11 sell-side analysts rate this a Buy with a mean 1-yr target of $165.18 (implying +22% upside).
Moat. Net margin 15% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 30% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $165.18 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $241.84 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $358.76 if current growth sustains into durable earnings power.
30. SE — Sea Limited · score 72.7
Internet Retail · price $105.31 · 1Y $140.26 · 5Y $205.35 · 10Y $304.62
FCF $4.5b B · Rev +36.4% A · D/E 0.28 A- · P/E 41.5x C · PEG 1.51 C+
Why now. Internet Retail · market cap $64.5b. Down 47% from 52-week high of $199.30 — deep drawdown territory. Revenue growing +36% — in hypergrowth territory. 28 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $140.26 (implying +33% upside).
Moat. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. $64.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Down 47% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Beta 1.55 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. Trailing P/E 41x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $140.26 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $205.35 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $304.62 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.